Consensus on standardized later-line systemic therapy for hepatocellular carcinoma
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Acta Pharmacologica Sinica, Published online: 19 November 2026; doi:10.1038/s41401-026-01973-9 Montelukast repurposed as a USP2 inhibitor induces c-Myc degradation and suppresses diffuse large B-cell lymphoma
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Acta Pharmacologica Sinica, Published online: 13 November 2026; doi:10.1038/s41401-026-01957-9 Structure-based virtual screening with AlphaFold identifies CLIP1-LTK inhibitors
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.